undefined
MANELoading price...
Overview
Previous Close59.98
Open60.06
Ask70.00
Bid65.00
Day's Range59.24 - 69.44
52 Week Range32.00 - 69.57
PE Ratio(TTM)--
Market Cap2.57B
Volume631.7k
Avg. Volume458.49k
12 Months Earnings-70.00M
12 Months Revenue0.00
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 71.56M | 71.56M | 26.38M | 17.32M |
| Profit after Tax (Net Income) | -70.00M | -70.00M | -26.49M | -16.49M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: New Haven, United States
Website: https://www.veradermics.com
CEO & Director: Dr. Reid Waldman M.D.
About Company:
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.